Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 143

1.

Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy.

Eilers RE Jr, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, Lacouture ME.

J Natl Cancer Inst. 2010 Jan 6;102(1):47-53. doi: 10.1093/jnci/djp439. Epub 2009 Dec 9.

PMID:
20007525
[PubMed - indexed for MEDLINE]
Free Article
2.

Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.

Osio A, Mateus C, Soria JC, Massard C, Malka D, Boige V, Besse B, Robert C.

Br J Dermatol. 2009 Sep;161(3):515-21. doi: 10.1111/j.1365-2133.2009.09214.x. Epub 2009 Apr 10.

PMID:
19466958
[PubMed - indexed for MEDLINE]
3.

Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.

Tejwani A, Wu S, Jia Y, Agulnik M, Millender L, Lacouture ME.

Cancer. 2009 Mar 15;115(6):1286-99. doi: 10.1002/cncr.24120.

PMID:
19170238
[PubMed - indexed for MEDLINE]
Free Article
4.

The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18).

Wagner LI, Berg SR, Gandhi M, Hlubocky FJ, Webster K, Aneja M, Cella D, Lacouture ME.

Support Care Cancer. 2013 Apr;21(4):1033-41. doi: 10.1007/s00520-012-1623-4. Epub 2012 Nov 7.

PMID:
23128934
[PubMed - indexed for MEDLINE]
5.

Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.

Joshi SS, Ortiz S, Witherspoon JN, Rademaker A, West DP, Anderson R, Rosenbaum SE, Lacouture ME.

Cancer. 2010 Aug 15;116(16):3916-23. doi: 10.1002/cncr.25090.

PMID:
20564072
[PubMed - indexed for MEDLINE]
Free Article
6.

Infections complicating mycosis fungoides and S├ęzary syndrome.

Axelrod PI, Lorber B, Vonderheid EC.

JAMA. 1992 Mar 11;267(10):1354-8.

PMID:
1740857
[PubMed - indexed for MEDLINE]
7.

Primary hyperhidrosis increases the risk of cutaneous infection: a case-control study of 387 patients.

Walling HW.

J Am Acad Dermatol. 2009 Aug;61(2):242-6. doi: 10.1016/j.jaad.2009.02.038. Epub 2009 Apr 23.

PMID:
19395123
[PubMed - indexed for MEDLINE]
8.

Clinical management of EGFRI dermatologic toxicities: US perspective.

Lacouture ME, Cotliar J, Mitchell EP.

Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):17-21.

PMID:
18154214
[PubMed - indexed for MEDLINE]
9.

Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.

Tan EH, Chan A.

Ann Pharmacother. 2009 Oct;43(10):1658-66. doi: 10.1345/aph.1M241. Epub 2009 Sep 15. Review.

PMID:
19755624
[PubMed - indexed for MEDLINE]
10.

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.

Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A.

Support Care Cancer. 2010 Apr;18(4):509-22. doi: 10.1007/s00520-009-0744-x. Epub 2010 Feb 10.

PMID:
20145956
[PubMed - indexed for MEDLINE]
11.

Preemptive management of dermatologic toxicities associated with epidermal growth factor receptor inhibitors.

Boucher J, Olson L, Piperdi B.

Clin J Oncol Nurs. 2011 Oct;15(5):501-8. doi: 10.1188/11.CJON.501-508.

PMID:
21951736
[PubMed - indexed for MEDLINE]
12.
13.

Clinical management of EGFRI dermatologic toxicities: the Japanese perspective.

Yamazaki N, Muro K.

Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):27-8.

PMID:
18159648
[PubMed - indexed for MEDLINE]
14.

Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: a case series and a literature review of therapeutic approaches.

Nikolaou V, Stratigos A, Antoniou C, Kiagia M, Nikolaou C, Katsambas A, Syrigos K.

Dermatology. 2010;220(3):243-8. doi: 10.1159/000277430. Epub 2010 Jan 22. Review.

PMID:
20110632
[PubMed - indexed for MEDLINE]
15.

[Skin signs associated with epidermal growth factor inhibitors].

Hannoud S, Rixe O, Bloch J, Le Pelletier F, Lebrun-Vignes B, Doarika A, Khayat D, Chosidow O.

Ann Dermatol Venereol. 2006 Mar;133(3):239-42. French.

PMID:
16800173
[PubMed - indexed for MEDLINE]
16.

Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.

Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME.

Oncologist. 2007 May;12(5):610-21. Review.

PMID:
17522250
[PubMed - indexed for MEDLINE]
Free Article
17.

Methicillin-resistant Staphylococcus aureus infections in vascular surgery: increasing prevalence.

Taylor MD, Napolitano LM.

Surg Infect (Larchmt). 2004 Summer;5(2):180-7.

PMID:
15353115
[PubMed - indexed for MEDLINE]
18.

Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).

Balagula Y, Barth Huston K, Busam KJ, Lacouture ME, Chapman PB, Myskowski PL.

Invest New Drugs. 2011 Oct;29(5):1114-21. doi: 10.1007/s10637-010-9567-3. Epub 2010 Oct 27.

PMID:
20978926
[PubMed - indexed for MEDLINE]
19.

Skin infections in 401 renal transplant recipients in southern Turkey.

Dicle O, Parmaksizoglu B, Gurkan A, Tuncer M, Demirbas A, Yilmaz E.

Exp Clin Transplant. 2009 Jun;7(2):133-6.

PMID:
19715520
[PubMed - indexed for MEDLINE]
Free Article
20.

Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.

Amitay-Laish I, David M, Stemmer SM.

Oncologist. 2010;15(9):1002-8. doi: 10.1634/theoncologist.2010-0063. Epub 2010 Aug 13.

PMID:
20709888
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk